

Performance in Initiating Clinical Trials Q4 2017-2018  
70 day benchmark - first participant recruited within 70 days

| Ethics Committee Number | IRAS Number | Name of Trial   | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site confirmed by Sponsor | Date Site confirmed | Date Site Ready to Start | Date of First Patient Recruited | Target Met | Source of Delay | Comments  |
|-------------------------|-------------|---|-------------------|--------------------|-------------------|--------------------------------|---------------------|--------------------------|---------------------------------|------------|-----------------|---|
| 15/EM/0510              | 209020      | A RANDOMISED CONTROLLED TRIAL OF ANTIPSYCHOTIC MEDICATION IN COMPARISON TO PSYCHOLOGICAL INTERVENTION AND A COMBINED TREATMENT IN CHILDREN AND YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A FEASIBILITY STUDY   | 22/03/2017        | 04/05/2017         | 09/02/2017        | 04/05/2017                     | 05/05/2017          | 05/05/2017               | 01/06/2017                      | Yes        |                 |   |
| 16/LO/1820              | 212826      | Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa (OPIANT)  | 17/06/2016        | 23/05/2017         | 25/01/2017        | 19/05/2017                     | 23/05/2017          | 23/05/2017               |                                 | No         | NHS and Sponsor | Study stopped following discussions between site and sponsor due to unforeseen circumstances regarding staff shortages in very small department |
| 17/SC/0068              | 215219      | Non-contact infrared thermometers for measuring body temperature in acutely ill children: a method comparison study   | 24/01/2017        | 23/05/2017         | 17/03/2017        | 08/05/2017                     | 23/05/2017          | 23/05/2017               | 09/06/2017                      | Yes        |                 |   |
| 16/SC/0435              | 212314      | 54135419TRD3008 An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression Safety and Sustainance of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-3) | 07/07/2016        | 20/06/2017         | 14/03/2017        | 21/06/2017                     | 27/06/2017          | 19/07/2017               | 11/08/2017                      | Yes        |                 |   |
| 16/LO/1377              | 197114      | A multicentre randomised controlled trial to examine whether the addition of a patient and carer skills-sharing intervention improves long-term patient wellbeing following hospital treatment for anorexia nervosa   | 22/11/2016        | 30/06/2017         | 26/10/2016        | 30/06/2017                     | 03/07/2017          | 03/07/2017               | 16/08/2017                      | Yes        |                 |   |

Performance in Initiating Clinical Trials Q4 2017-2018  
70 day benchmark - first participant recruited within 70 days

| Ethics Committee Number | IRAS Number | Name of Trial   | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site confirmed by Sponsor | Date Site confirmed | Date Site Ready to Start | Date of First Patient Recruited | Target Met | Source of Delay | Comments |
|-------------------------|-------------|---|-------------------|--------------------|-------------------|--------------------------------|---------------------|--------------------------|---------------------------------|------------|-----------------|----------|
| 17/WA/0085              | 219483      | TACKling chronic depression - adapting and testing a technology supported patient-centred and solution-focused intervention (DIALOG+) for people with chronic depression (TACK)   | 24/07/2017        | 06/09/2017         | 31/03/2017        | 12/07/2017                     | 08/09/2017          | 08/09/2017               | 06/10/2017                      | Yes        |                 |          |
| 17/WM/0146              | 220303      | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer s Disease; DEME 32112  | 05/04/2017        | 26/09/2017         | 21/08/2017        | 25/09/2017                     | 26/09/2017          | 26/09/2017               | 22/11/2017                      | Yes        |                 |          |
| 16/SC/0654              | 214951      | Effects of Modulating the Immune System with Prebiotics on Cognition and Weight in Patients with Psychosis  | 07/12/2016        | 06/04/2017         | 06/02/2017        | 06/04/2017                     | 07/04/2017          | 07/04/2017               | 17/05/2017                      | Yes        |                 |          |
| 16/SC/0553              | 172518      | A randomised, parallel group, double blind, placebo controlled, add on clinical trial to investigate whether the lithium mimetic, ebselen, can reduce symptoms of hypomania and mania in bipolar patients experiencing an acute episode of mania or hypomania | 04/07/2016        | 02/10/2017         | 12/07/2017        | 25/09/2017                     | 02/10/2017          | 03/10/2017               | 20/10/2017                      | Yes        |                 |          |
| 16/LO/1507              | 193921      | Randomised Controlled trial, schizophrenia and psychotic disorders  | 30/05/2017        | 07/02/2018         | 21/12/2016        | 07/02/2018                     | 07/02/2018          | 07/02/2018               | 22/02/2018                      | Yes        |                 |          |